MIMEDX Investor Presentation Highlights Clear Technique for Worth Creation

MiMedx Group, Inc

MiMedx Group, Inc

Decisive, Constructive Actions Taken to Stabilize and Remodel MIMEDX Have Established Robust, New Basis for Development

Firm Urges Shareholders to Vote “FOR” Each Extremely Certified Director Nominees – James L. Bierman and Phyllis Gardner, MD – on the WHITE Proxy Card

MARIETTA, Ga., Could 18, 2022 (GLOBE NEWSWIRE) — MiMedx Group, Inc. (NASDAQ: MDXG) (“MIMEDX” or the “Firm”), a transformational placental biologics firm, right now filed an investor presentation with the US Securities and Change Fee in reference to its 2022 Annual Assembly of Shareholders, which is scheduled to be held on June 7, 2022. The presentation, and different necessary shareholder supplies, can be found at www.VoteMIMEDX.com.

Within the presentation, MIMEDX outlines the numerous progress the Firm has made over the past three years beneath its present management group and supplies transparency round various matters and initiatives pertinent to shareholders, together with:

  • Technique for Lengthy-Time period Worth Creation: MIMEDX has taken decisive motion to efficiently maintain, stabilize and develop the Firm over the past three years, and has a transparent technique for long-term shareholder worth creation. MIMEDX lately introduced a 3rd consecutive quarter of double-digit progress in its Superior Wound Care & Surgical Restoration merchandise, demonstrating robust execution. As well as, the realignment of the Firm’s inner enterprise construction positions MIMEDX to additional develop, innovate, and drive sustained progress, and in addition speed up the beginning of trial enrollment in its Knee Osteoarthritis medical trial program.

  • Company Governance Practices and Board {Qualifications}: MIMEDX’s Board has been solely reconstituted since 2019 and is made up of 9 extremely certified administrators with the vital abilities, life sciences expertise and enterprise acumen to supervise the Firm’s technique. The Board has adopted roughly 70 best-practice and shareholder-friendly company governance reforms over the past three years and resolved all legacy firm points, demonstrating its dedication to best-in-class governance practices.

  • Govt Compensation: MIMEDX’s govt compensation, decided in partnership with an impartial marketing consultant, is predicated on a philosophy of organizational and particular person efficiency and is aligned with shareholder worth by efficiency components, together with income progress, and important equity-based parts of whole compensation. It’s nicely throughout the vary of MIMEDX friends and is intently aligned with shareholder pursuits. For instance, partially because of the decline within the Firm’s inventory value, none of MIMEDX’s govt officers acquired annual money bonuses at their 2021 goal ranges.

Your Vote Is Essential, No Matter How Many Or How Few Shares You Personal

You possibly can vote by web, phone or by signing and courting the WHITE proxy card and mailing it within the envelope supplied.

When you’ve got any questions on the way to vote your shares, or want further help, please contact:

MORROW
SODALI

[email protected]
(203) 658-9400
or
Toll Free (800) 662-5200

About MIMEDX

MIMEDX is a transformational placental biologics firm, growing and distributing placental tissue allografts with patent-protected, proprietary processes for a number of sectors of healthcare. As a pioneer in placental tissue engineering, we’ve got each a industrial enterprise, targeted on addressing the wants of sufferers with acute and continual non-healing wounds, and a promising late-stage pipeline focused at lowering ache and bettering perform for sufferers with degenerative musculoskeletal circumstances. We derive our merchandise from human placental tissues and course of these tissues utilizing our proprietary strategies, together with the PURION® course of. We make use of Present Good Tissue Practices, Present Good Manufacturing Practices, and terminal sterilization to provide our allografts. MIMEDX has provided over two million allografts, by each direct and consignment shipments. For added info, please go to www.mimedx.com.

Essential Cautionary Assertion

This press launch contains forward-looking statements. Statements relating to: (i) our perception that the long run technique we’ve got chosen is in the very best pursuits of our shareholders; (ii) our perception that as we proceed to execute towards our acknowledged goals and navigate our subsequent section of progress, we’re nicely positioned for the longer term; and (iii) our perception that the expertise, experience and dedication of the MIMEDX management group, as overseen by our Board of Administrators, will assist place the Firm for additional future success and worth creation. Extra forward-looking statements could also be recognized by phrases equivalent to “consider,” “anticipate,” “might,” “plan,” “aim,” “outlook,” “potential,” “will,” “preliminary,” and related expressions, and are based mostly on administration’s present beliefs and expectations.

Ahead-looking statements are topic to dangers and uncertainties, and the Firm cautions buyers towards putting undue reliance on such statements. Precise outcomes might differ materially from these set forth within the forward-looking statements. Elements that would trigger precise outcomes to vary from expectations embrace: (i) future gross sales are unsure and are affected by competitors, entry to prospects, affected person entry to healthcare suppliers, and plenty of different components; (ii) the standing, timing, outcomes and anticipated outcomes of the Firm’s medical trials, deliberate regulatory submissions and regulatory approvals, and our expectations relating to our potential to doubtlessly speed up the timing of any trial or regulatory submission, relying on various components together with favorable trial outcomes, affected person entry, and our potential to fabricate in accordance with Present Good Manufacturing Practices (CGMP) and applicable chemistry and manufacturing controls; (iii) the Firm might change its plans resulting from unexpected circumstances, or delays in analyzing and auditing outcomes, and will delay or alter the timeline for future trials, analyses, or public bulletins; (iv) our entry to hospitals and well being care supplier amenities could possibly be restricted on account of the continuing COVID-19 pandemic or different components; (v) the outcomes of scientific analysis are unsure and will have little or no worth; (vi) our potential to promote our merchandise in different nations depends upon various components together with enough ranges of reimbursement, regulatory approvals, market acceptance of novel therapies, and our potential to construct and handle a direct gross sales pressure or third celebration distribution relationship; (vii) the effectiveness of amniotic tissue as a remedy for specific indications or circumstances is the topic of additional scientific and medical research; and (viii) we might alter the timing and quantity of deliberate expenditures for analysis and improvement based mostly on the outcomes of medical trials and different regulatory developments. The Firm describes further dangers and uncertainties within the Threat Elements part of its most up-to-date annual report and quarterly studies filed with the Securities and Change Fee. Any forward-looking statements communicate solely as of the date of this press launch and the Firm assumes no obligation to replace any forward-looking assertion.

Essential further info

The Firm, its administrators, director nominees and sure of its govt officers are individuals within the solicitation of proxies from the Firm’s shareholders in reference to the 2022 annual assembly of shareholders (the “2022 Annual Assembly”). The Firm has filed a definitive proxy assertion and a WHITE proxy card with the Securities and Change Fee (the “SEC”) in reference to any such solicitation of proxies from the Firm’s shareholders. SHAREHOLDERS OF THE COMPANY ARE STRONGLY ENCOURAGED TO READ THE PROXY STATEMENT, ACCOMPANYING WHITE PROXY CARD AND ALL OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY CONTAIN IMPORTANT INFORMATION. The Firm’s definitive proxy assertion for the 2022 Annual Assembly accommodates info relating to the direct and oblique pursuits, by safety holdings or in any other case, of the Firm’s administrators, director nominees and govt officers within the issues to be acted upon on the 2022 Annual Assembly. Info relating to subsequent modifications to their holdings of the Firm’s securities could be discovered within the SEC filings on Varieties 3, 4 and 5, which can be found on the Firm’s web site at www.mimedx.com or by the SEC’s web site at www.sec.gov . Info will also be discovered within the Firm’s different SEC filings, together with its Annual Report on Type 10-Okay for the yr ended December 31, 2021. Shareholders are in a position to receive the definitive proxy assertion, any amendments or dietary supplements to the proxy assertion and different paperwork filed by the Firm with the SEC at no cost on the SEC’s web site at www.sec.gov. Copies are additionally accessible at no cost on the Firm’s web site at www.mimedx.com.

Contacts

Traders:
Jack Howarth
Investor Relations
404-360-5681
[email protected]

Media:
Hilary Dixon
Company & Strategic Communications
404-323-4779
[email protected]

Leave a Comment